
DiaMedica Therapeutics DMAC
$ 9.4
0.7%
Quarterly report 2025-Q3
added 11-12-2025
DiaMedica Therapeutics Total Assets 2011-2025 | DMAC
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets DiaMedica Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 54.2 M | 34.4 M | 45.6 M | 28.1 M | 9.05 M | 18.3 M | 1.8 M | 1.87 M | 222 K | 282 K | 2.91 M | 3.85 M | 6.33 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 54.2 M | 222 K | 15.9 M |
Quarterly Total Assets DiaMedica Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 57 M | 31.5 M | 38.8 M | 46.3 M | 52.5 M | 56.8 M | 49.3 M | 54.2 M | 58.1 M | 62 M | 30.2 M | 34.4 M | 37 M | 39.3 M | 42.2 M | 45.6 M | 48.7 M | 21.8 M | 24.4 M | 28.1 M | 28.1 M | 28.1 M | 28.1 M | 9.05 M | 9.05 M | 9.05 M | 9.05 M | 18.3 M | 18.3 M | 18.3 M | 18.3 M | 1.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 62 M | 1.8 M | 32.9 M |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
2.03 B | - | 2.43 % | $ 254 M | ||
|
AlloVir
ALVR
|
119 M | - | 4.14 % | $ 49.1 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
18.1 B | - | - | $ 40.3 B | ||
|
Ascendis Pharma A/S
ASND
|
1.18 B | $ 220.27 | 4.81 % | $ 5 B | ||
|
Can-Fite BioPharma Ltd.
CANF
|
9.12 M | $ 0.28 | -2.28 % | $ 609 M | ||
|
Alterity Therapeutics Limited
ATHE
|
41.4 M | $ 3.3 | -3.51 % | $ 7.94 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
15.2 M | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
14.8 M | - | -18.52 % | $ 27.3 M | ||
|
Aptorum Group Limited
APM
|
16.1 M | $ 1.29 | -3.01 % | $ 7.03 M | ||
|
Biophytis SA
BPTS
|
12 M | - | -13.47 % | $ 169 M | ||
|
Институт стволовых клеток человека
ISKJ
|
1.51 B | - | - | - | ||
|
ARCA biopharma
ABIO
|
396 M | - | 1052.0 % | $ 415 M | ||
|
Arbutus Biopharma Corporation
ABUS
|
144 M | $ 4.75 | 1.61 % | $ 788 M | ||
|
Aclaris Therapeutics
ACRS
|
220 M | $ 3.26 | -3.12 % | $ 252 M | ||
|
Acasti Pharma
ACST
|
72 M | - | 4.01 % | $ 150 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
283 M | - | -15.15 % | $ 60.3 M | ||
|
Aeglea BioTherapeutics
AGLE
|
608 M | - | - | $ 1.01 B | ||
|
Albireo Pharma
ALBO
|
302 M | - | -0.23 % | $ 916 M | ||
|
Alpine Immune Sciences
ALPN
|
287 M | - | - | $ 2.17 B | ||
|
Ampio Pharmaceuticals
AMPE
|
5.74 M | - | -11.43 % | $ 502 K | ||
|
Amphastar Pharmaceuticals
AMPH
|
1.58 B | $ 25.27 | -2.43 % | $ 1.22 B | ||
|
Applied Molecular Transport
AMTI
|
107 M | - | - | $ 10.1 M | ||
|
Anika Therapeutics
ANIK
|
271 M | $ 9.57 | 0.84 % | $ 140 M | ||
|
BioNTech SE
BNTX
|
22.5 B | $ 94.73 | -1.32 % | $ 27.2 B | ||
|
Arena Pharmaceuticals
ARNA
|
785 M | - | -6.81 % | $ 3.04 B | ||
|
Athersys
ATHX
|
60.2 M | - | 3.77 % | $ 22.4 M | ||
|
Acer Therapeutics
ACER
|
11.6 M | - | 2.71 % | $ 14 M | ||
|
Avenue Therapeutics
ATXI
|
2.67 M | - | -52.27 % | $ 4.45 M | ||
|
AVROBIO
AVRO
|
101 M | - | 1083.1 % | $ 745 M | ||
|
Axon Enterprise
AXON
|
4.47 B | $ 566.18 | -2.56 % | $ 42.9 B | ||
|
Ayala Pharmaceuticals
AYLA
|
7.77 M | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
124 M | $ 2.34 | 2.59 % | $ 14.7 M | ||
|
AstraZeneca PLC
AZN
|
104 B | $ 89.78 | -0.57 % | $ 96.9 B | ||
|
Acorda Therapeutics
ACOR
|
109 M | - | -24.86 % | $ 820 K | ||
|
Brickell Biotech
BBI
|
11.6 M | - | -5.38 % | $ 6.06 M | ||
|
Burford Capital Limited
BUR
|
3.11 B | $ 9.09 | -0.55 % | $ 1.5 B | ||
|
BeiGene, Ltd.
BGNE
|
5.92 B | - | 0.49 % | $ 251 B | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
1.08 B | $ 11.54 | 0.87 % | $ 746 M | ||
|
Biogen
BIIB
|
28 B | $ 174.42 | 1.11 % | $ 25.4 B | ||
|
BioVie
BIVI
|
21.6 M | $ 1.42 | -5.96 % | $ 2.1 M | ||
|
Abeona Therapeutics
ABEO
|
64 M | $ 5.36 | -2.99 % | $ 115 M | ||
|
Dynavax Technologies Corporation
DVAX
|
986 M | $ 10.85 | -0.14 % | $ 1.41 B | ||
|
ADiTx Therapeutics
ADTX
|
32.1 M | $ 2.3 | -3.0 % | $ 30.3 K | ||
|
Bellicum Pharmaceuticals
BLCM
|
23.8 M | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
226 M | - | -7.31 % | $ 87 M | ||
|
Advaxis
ADXS
|
16.6 M | - | -9.65 % | $ 45.9 M | ||
|
Завод ДИОД
DIOD
|
1.4 B | - | - | - | ||
|
Фармсинтез
LIFE
|
2.05 B | - | - | - | ||
|
BioLineRx Ltd.
BLRX
|
38.9 M | $ 3.17 | -1.86 % | $ 908 M | ||
|
bluebird bio
BLUE
|
619 M | - | - | $ 546 M |